Ergomed Stock Price, News & Analysis (LON:ERGO)

GBX 288
-3.00 (-1.03 %)
(As of 09/20/2019 04:00 PM ET)
Today's Range
286.40
Now: GBX 288
290
50-Day Range
288
MA: GBX 321.64
340
52-Week Range
145
Now: GBX 288
344
Volume9,290 shs
Average Volume28,490 shs
Market Capitalization£135.26 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Ergomed plc provides clinical research, and drug development and safety and medical information services in the United Kingdom and internationally. The company offers clinical development, trial management, and pharmacovigilance services for pharmaceutical and generics companies, as well as small and mid-sized drug development companies. It focuses on various therapeutic areas, including oncology, neurology, and immunology, as well as the development of orphan drugs. Read More…

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1483-503205

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£54.11 million
Cash FlowGBX 11.08 per share
Book ValueGBX 62.80 per share

Profitability

Miscellaneous

Employees700
Market Cap£135.26 million
Next Earnings Date9/25/2019 (Estimated)
OptionableNot Optionable

Receive ERGO News and Ratings via Email

Sign-up to receive the latest news and ratings for ERGO and its competitors with MarketBeat's FREE daily newsletter.


Ergomed (LON:ERGO) Frequently Asked Questions

What is Ergomed's stock symbol?

Ergomed trades on the London Stock Exchange (LON) under the ticker symbol "ERGO."

How were Ergomed's earnings last quarter?

Ergomed PLC (LON:ERGO) announced its earnings results on Monday, September, 18th. The company reported $1.20 earnings per share (EPS) for the quarter. The company had revenue of $22.91 million for the quarter. View Ergomed's Earnings History.

When is Ergomed's next earnings date?

Ergomed is scheduled to release their next quarterly earnings announcement on Wednesday, September 25th 2019. View Earnings Estimates for Ergomed.

What price target have analysts set for ERGO?

1 brokers have issued twelve-month price objectives for Ergomed's shares. Their forecasts range from GBX 267 to GBX 267. On average, they expect Ergomed's share price to reach GBX 267 in the next twelve months. This suggests that the stock has a possible downside of 7.3%. View Analyst Price Targets for Ergomed.

What is the consensus analysts' recommendation for Ergomed?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ergomed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ergomed.

Has Ergomed been receiving favorable news coverage?

News coverage about ERGO stock has trended negative this week, according to InfoTrie. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ergomed earned a daily sentiment score of -2.9 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Ergomed.

Who are some of Ergomed's key competitors?

What other stocks do shareholders of Ergomed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ergomed investors own include Dicerna Pharmaceuticals (DRNA), AbbVie (ABBV), Science Applications International (SAIC), Axsome Therapeutics (AXSM), Tilray (TLRY), NIO (NIO), Celgene (CELG), Carbon Black (CBLK), BioMarin Pharmaceutical (BMRN) and Balchem (BCPC).

Who are Ergomed's key executives?

Ergomed's management team includes the folowing people:
  • Dr. Miroslav Reljanovic, Founder & Exec. Chairman (Age 60)
  • Dr. Jan Petracek, COO & Director (Age 43)
  • Mr. Stuart Robert Jackson, CFO & Director (Age 59)
  • Ms. Sanja Juric, Gen. Counsel & Company Sec.
  • Dr. Michael Forstner, Head of Risk Management & Pharmacoepidemiology

How do I buy shares of Ergomed?

Shares of ERGO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Ergomed's stock price today?

One share of ERGO stock can currently be purchased for approximately GBX 288.

How big of a company is Ergomed?

Ergomed has a market capitalization of £135.26 million and generates £54.11 million in revenue each year. Ergomed employs 700 workers across the globe.View Additional Information About Ergomed.

What is Ergomed's official website?

The official website for Ergomed is http://www.ergomedplc.com/.

How can I contact Ergomed?

Ergomed's mailing address is 26-24 Frederick Sanger Road, GUILDFORD, GU2 7YD, United Kingdom. The company can be reached via phone at +44-1483-503205.


MarketBeat Community Rating for Ergomed (LON ERGO)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  227 (Vote Outperform)
Underperform Votes:  140 (Vote Underperform)
Total Votes:  367
MarketBeat's community ratings are surveys of what our community members think about Ergomed and other stocks. Vote "Outperform" if you believe ERGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ERGO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel